Fidelity National Information Servcs Inc vs TransMedics Group Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.9 (market cap $22.05B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Fidelity National Information Servcs Inc is far larger — about 7.1× TransMedics Group Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FIS | TMDX | |
|---|---|---|
Market Cap | $22.05B | $3.10B |
Sector | Technology | Technology |
52-Week High | $72.77 | $150.42 |
52-Week Low | $37.72 | $61.99 |
Enterprise Value | $42.56B | $3.49B |
Dividend Yield | 4.12% | — |
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.10, down 0.96% with bearish technical signals. The company shows improving fundamentals with Q2 2026 earnings beat and 5.3% revenue growth, though it lowered full-year guidance. Valuation appears attractive with P/E of 6.57 and P/S of 1.82. Recent expansion into APAC markets and treasury software recognition provide growth catalysts. Cash flow improved significantly from 2025's negative $1.35B to projected positive $188M for 2026.
FIS presents a mixed outlook with strong banking solutions growth offset by capital markets weakness. The 19% upside to consensus price target of $50.18 offers potential, but execution risks remain given the guidance reduction. Investors should weigh the attractive valuation against operational challenges in achieving sustained profitability improvement.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Trailing returns across standard periods
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →